Biodexa Pharmaceuticals Plc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $6.9m
$7.6m +9.75%
$1.9m -74.49%
$674k -65.22%
$343k -49.11%
$578k +68.51%
$699k +20.93%
$381k -45.49%
$412k +8.14%
$533k +29.37%
$0 -100.00%
Cost of Goods and Services Sold $667k
$926k +38.83%
$236k -74.49%
$82k -65.22%
$42k -49.11%
$70k +68.51%
$85k +20.93%
$46k -45.49%
$413k +788.45%
$2.2m +441.28%
$4.0m +77.38%
Gross Profit (derived) $6.3m
$6.7m +6.65%
$1.7m -74.49%
$592k -65.22%
$301k -49.11%
$508k +68.51%
$614k +20.93%
$335k -45.49%
$3.0m +788.45%
$152k -94.89%
($4.0m) -2705.92%
Research and development $7.8m $10.2m $9.4m $7.8m $6.1m $4.7m $5.1m $4.1m $5.4m $4.0m
Operating Lease Income $557k
Operating expenses:
Loss from operations ($30.6m)
($17.6m) +42.53%
($11.8m) +32.79%
($11.3m) +4.21%
($23.0m) -103.57%
($7.0m) +69.63%
($8.9m) -27.64%
($8.0m) +10.28%
($9.2m) -14.79%
($8.6m) +6.02%
Interest Expense On Lease Liabilities $20k $36k $43k $28k $19k $10k $229k
Interest Income $1.3m $415k $2k $492k $1k $936k $497k $570k $3.4m $2.4m $89k
Other Income $15k $12k $24k $22k $14k $31k $152k
Non-Operating Income (Expense) $15k $12k $24k $22k $14k $31k $152k
Current Tax Expense (Income) ($1.9m) ($1.3m) ($2.0m) ($1.8m) ($1.3m) $646k
Income Tax Expense Continuing Operations ($9.2m) ($1.3m) ($2.0m) ($1.8m) ($1.3m) $646k ($832k) ($406k) ($250k) ($105k) ($105k)
Basic Earnings (Loss) Per Share ($0.02) ($0.00) ($0.00) ($2.50)
Diluted Earnings (Loss) Per Share ($1.55) ($0.02) ($0.00) ($0.00) ($2.50)
Additional Financial Items
Administrative Expense $5.1m $3.1m $4.4m $3.8m $5.0m $2.9m $4.5m $4.3m $3.8m $4.8m
Applicable Tax Rate $0 $0 $0 $0 $0
Depreciation Right of Use Assets $303k $118k $190k $166k $137k $135k $136k
Finance Costs $73k $166k $587k $97k $431k $44k $53k $41k $165k $229k
Finance Income $1.3m $415k $2k $492k $1k $936k $497k $570k $3.4m $2.4m
Impairment Loss Recognised In Profit Or Loss Goodwill $2.3m
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill $9.3m
Postemployment Benefit Expense Defined Benefit Plans $28k $10k $4k $22k $17k
Postemployment Benefit Expense Defined Contribution Plans $206k $158k $149k $90k $75k $71k $98k $86k $67k $69k
Profit Loss Before Tax ($29.3m) ($17.3m) ($12.4m) ($10.9m) ($23.5m) ($6.1m) ($8.5m) ($7.5m) ($6.0m) ($6.5m)
Profit Loss From Operating Activities ($30.6m) ($17.6m) ($11.8m) ($11.3m) ($23.0m) ($7.0m) ($8.9m) ($8.0m) ($9.2m) ($8.6m)
Finance expense ($73k) ($166k) ($587k) ($97k) ($431k) ($44k) ($53k) ($41k) ($165k) ($229k)
Taxation $9.2m $1.3m $2.0m $1.8m $1.3m $646k $832k $406k $250k $105k
Loss for the year attributable to the owners of the parent ($20.2m) ($16.1m) ($15.0m) ($10.1m) ($22.2m) ($5.5m) ($7.7m) ($7.1m) ($5.7m) ($6.4m)
Exchange gains arising on translation of foreign operations $508k $3k
Net Foreign Exchange Loss $130k ($140k) $387k ($3k)
Total other comprehensive income net of tax $3.2m ($1.2m) ($2.7m) ($207k) $508k $3k
Total comprehensive loss attributable to the owners of the parent ($16.9m) ($17.3m) ($17.7m) ($10.3m) ($21.7m) ($5.5m) ($7.7m) ($7.1m) ($5.7m) ($6.4m)